BIOLARGO, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
May 19, 2022 at 03:31 pm
Share
Item 7.01 Regulation FD Disclosure.
On May 17, 2022, BioLargo, Inc. published the press release which is attached
hereto as Exhibit 99.1 and is incorporated herein by reference.
In conjunction with a webcast to be presented on May 19, 2022, at 1:00 p.m.
Pacific Time, BioLargo, Inc., intends to present the slides attached as Exhibit
99.2, which is incorporated herein by reference.
The information in this Item 7.01 of this Current Report on Form 8-K and
Exhibits 99.1 and 99.2 attached hereto shall not be deemed "filed" for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section or Sections 11 and 12(a)(2) of the
Securities Act of 1933, as amended. The information contained in this Item 7.01,
in the press release attached as Exhibit 99.1, and in the slide presentation
attached as Exhibit 99.2 to this Current Report shall not be incorporated by
reference into any filing with the SEC made by the Company, whether made before
or after the date hereof, regardless of any general incorporation language in
such filing. The Company undertakes no duty or obligation to update or revise
the information contained in this report, although it may do so from time to
time as its management believes is appropriate. Any such updating may be made
through the filing of other reports or documents with the SEC, through press
releases or through other public disclosures. For important information about
forward looking statements, see the information under the heading "Safe Harbor
Act" in Exhibit 99.1 attached hereto, and on the first slide under the heading
"Safe Harbor Statement" in Exhibit 99.2 attached hereto.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press release
99.2 Presentation slides
104 Cover Page Interactive Data File (embedded within the Inline
XBRL document)
BioLargo, Inc. is a cleantech and life sciences innovator and engineering services solution provider. The Company invents, develops, and commercializes platform technologies to solve challenging environmental problems like polyfluoroalkyl substances (PFAS) contamination, advanced water and wastewater treatment, industrial odor control, air quality control, infection control, and myriad environmental remediation challenges. The Companyâs segments include ONM Environmental, which manufactures and sells its odor and VOC control products and services, including its flagship product, CupriDyne Clean; BLEST, which provides professional engineering services supporting its internal business units; Clyra Medical, which develops and sells medical products based on its technology; BioLargo Canada, which is primary engaged in research and development activities; and Corporate Operations, which support the operating segments with legal, accounting, human resources, and other services.